Recurrences after nephron-sparing treatments of renal cell carcinoma: a competing risk analysis - Top-Institutions - MDSpire

Recurrences after nephron-sparing treatments of renal cell carcinoma: a competing risk analysis

  • By

  • Andreas Karlsson Rosenblad

  • Bassam Mazin Hashim

  • Per Lindblad

  • Börje Ljungberg

  • August 7, 2024

  • 0 min

Share

Top Institutions in Urology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Urologic Oncology
    • Surgical Oncology
    • Kidney Cancer Research

  • #2

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Urology
    • Oncology
    • Kidney Cancer

  • #3

    Dana-Farber/Brigham and Women’s Cancer Center
    Dana-Farber/Brigham and Women’s Cancer Center

    Boston, MA

    Key Differentiators

    • Medical Oncology
    • Urologic Oncology
    • Kidney Cancer Research

  • #4

    University of Texas MD Anderson Cancer Center
    University of Texas MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Urologic Oncology
    • Surgical Oncology
    • Kidney Cancer

  • #5

    Karolinska Institutet
    Karolinska Institutet

    Stockholm, N/A

    Key Differentiators

    • Urologic Oncology
    • Epidemiology
    • Kidney Cancer Research

Original Source(s)

Recurrences after nephron-sparing treatments of renal cell carcinoma: a competing risk analysis

  • by Andreas Karlsson Rosenblad, Bassam Mazin Hashim, Per Lindblad, Börje Ljungberg

  • August 7, 2024

Related Content

Dana-Farber’s Dr. Toni Choueiri Elected to the Association of American Physicians

Dana-Farber Cancer Institute’s Dr. Toni Choueiri, Director of the Lank Center for Genitourinary Oncology, was recently elected to one of the nation’s most prestigious medical organizations, The Association of American Physicians (AAP).

  • by

  • April 20, 2026

  • 2 min
Axitinib-Pembrolizumab and Adverse Event Management in Patients With Advanced Renal Cell Carcinoma

TROP-2 overexpression in papillary renal cell carcinoma supports its potential as a therapeutic target for antibody-drug-conjugate therapy